Title: AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Journal: International journal of cancer 20120615
Title: A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120501
Title: Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.
Journal: Blood cells, molecules & diseases 20120315
Title: Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.
Journal: Leukemia research 20110901
Title: Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110515
Title: AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer.
Journal: Current opinion in investigational drugs (London, England : 2000) 20101201
Title: Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Journal: Blood 20100923
Title: AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Journal: British journal of haematology 20100701
Title: Aurora kinase inhibitors as anti-cancer therapy.
Journal: Anti-cancer drugs 20100401
Title: Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Journal: Cell cycle (Georgetown, Tex.) 20090615
Title: Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Journal: Journal of medicinal chemistry 20090122
Title: Howard S, et al. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. Journal of Medicinal Chemistry (2009), 52(2), 379-388.
Title: Qi W, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005.
Title: Santo L, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15;17(10):3259-71
